SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
== Plot == Half Bad is set in a version of modern-day Europe, mainly Britain, in which witches and humans (Fains) live together. Witches are divided into Black (oppressed and written off as evil), and White, the latter making up the majority of the witch population. The 17-year-old protagonist, Nathan, is half White and half Black, or Half Code. His mother is dead, and his father, Marcus, is the most powerful and violent Black witch in history. Because of his parentage, Nathan's every move is monitored by the Council of White Witches. He is forced to follow a strict set of rules, but when he breaks one too many, he is taken away from his grandmother and entrusted into the care of a White witch, Celia. Trapped in a cage and abused by Celia, Nathan must escape before his seventeenth birthday, to find his father, and receive three gifts from him and his Gift. Otherwise, he will die.
==== Pharmaceutical copies ==== The pharmaceutical industry has revenues of hundreds of billions of dollars a year globally. With such a large industry counterfeiting and copyright infringement are serious issues, and hydrogen isotope fingerprinting has become a useful tool in verifying the authenticity of various drugs. As described in the preceding sections, the utility of DHRs is highest when combined with measurements of other isotope ratios. In an early study on the stable isotope compositions of tropicamide, hydrocortisone, quinine and tryptophan; carbon, nitrogen, oxygen and hydrogen stable isotopes were analyzed by EA-IRMS; clear distinctions were able to be made between manufacturers and even batches of the drugs based on their isotope signatures. In this study it was determined that the hydrogen and oxygen isotope ratios were the two best fingerprints for distinguishing between different drug sources. A follow-up study analyzing naproxen from various lots and manufacturers also showed similar ability to distinguish between sources of the drugs. The use of these isotope signatures could not only be used to distinguish between different manufacturers, but also between different synthetic pathways for the same compound. These studies relied on the natural variations that occurred in the synthesis of these drugs, but other studies have used starting ingredients that are intentionally labeled D and 13C, and showed that these labels could be traced into the final pharmaceutical product.
The socialists proposed the full integration of Spain into Europe, but when they took office the negotiations for the accession to the European Economic Community (EEC) were still blocked because of the "pause" in the enlargement imposed by the French president Giscard d'Estaing. However, the triumph in the presidential elections of the socialist François Mitterrand allowed rapid progress in the negotiations and so on June 12, 1985, the EEC accession treaty was signed and on January 1, 1986, Spain joined the EEC together with Portugal.
"Chorionic gonadotropin+beta [HCG];Csv";"Csv-Chorionic gonadotropin+beta chain; arb.stofk.(IS 75/589)";Clinical Biochemistry Laboratory "alpha-1-Fotoprotein;Csv";"Csv-alpha-1-Fotoprotein; arb.stofk.";Clinical Biochemistry Laboratory "Tick-borne encephalitis virus antibody; arb.k.(list; proc.);Csv";Tick-borne encephalitis virus antibody; Clinical Microbiology Laboratory "Cerebrospinal fluid group;Csv";"Csv-Nucleated cell type; count(list)";Clinical Biochemistry Laboratory "Erythrocytes;Csv";"Csv-Erythrocytes; count";Clinical Biochemistry Laboratory "Nucleated cells;Csv";"Csv-Nucleated cells; count";Clinical Biochemistry Laboratory "Nucleated cells;Csv";"Csv-Nucleated cells; count";Clinical Biochemistry Laboratory "Leukocytes(mononuclear);Lkc(Csv)";"Csv-Mononuclear cells; count";Clinical Biochemistry Laboratory "Leukocytes(mononuclear);Lkc(Csv)";"Csv-Leukocytes(mononuclear); count";Clinical Biochemistry Laboratory "Leukocytes (polynucleus);Lkc(Csv)";"Csv-Leukocytes(polynucleus); count";Clinical Biochemistry Laboratory "Leukocytes (polynuclear);Lkc(Csv)";"Csv-Polynuclear cells; count";Clinical Biochemistry Laboratory "Neurofilament light polypeptide;Csv";Csv(cell-free);Neuroimmunology Laboratory "Glucose;Csv";"Csv-Glucose; substance c.";Clinical Biochemistry Laboratory Alternatively formatted list: The following analyses (Normal Order Name; Designation in the laboratory; Laboratory) can be performed on cerebrospinal fluid (CSF) samples.
Sources: en.wikipedia.org
In February 2012, Ontario passed legislation to allow the expansion of an already existing drug-tracking system for publicly funded drugs to include those that are privately insured. This database will function to identify and monitor patient's attempts to seek prescriptions from multiple doctors or retrieve them from multiple pharmacies. Other provinces have proposed similar legislation, while some, such as Nova Scotia, have legislation already in effect for monitoring prescription drug use. These changes have coincided with other changes in Ontario's legislation to target the misuse of painkillers and high addiction rates to drugs such as oxycodone. As of 29 February 2012, Ontario passed legislation delisting oxycodone from the province's public drug benefit program. This was a first for any province to delist a drug based on addictive properties. The new law prohibits prescriptions for OxyNeo except to certain patients under the Exceptional Access Program including palliative care and in other extenuating circumstances. Patients already prescribed oxycodone will receive coverage for an additional year for OxyNeo, and after that, it will be disallowed unless designated under the exceptional access program. Much of the legislative activity has stemmed from Purdue Pharma's decision in 2011 to begin a modification of OxyContin's composition to make it more difficult to crush for snorting or injecting. The new formulation, OxyNeo, is intended to be preventive in this regard and retain its effectiveness as a painkiller.
Alkylation of guanine is the principal pharmacologically relevant event underlying melphalan’s therapeutic activity. This reaction produces crosslinks either between complementary DNA strands or within a single strand, typically involving guanine–guanine or adenine–adenine pairs. Such crosslinking disrupts DNA synthesis and RNA synthesis, processes essential for cell survival, leading to cytotoxicity in both dividing and non-dividing tumor cells.
Acetyl transacylase transfers the acetyl group of acetyl-CoA onto the sulfhydryl group of Acyl Carrier Protein (ACP), releasing CoA and forming acetyl-ACP. An equivalent reaction occurs for malonyl-CoA, in which malonyl transacylase transfers the malonyl group from malonyl-CoA to the sulfhydryl group of Acyl Carrier Protein (ACP), releasing CoA and forming malonyl-ACP. These two reactions are essential, as they prime the acetyl and malonyl groups for condensation in the subsequent chain elongation reaction step. After the production of acetyl-ACP and malonyl-ACP, fatty acid synthesis begins to cycle through repetitions of the following reaction sequence: condensation → reduction → dehydration → reduction. Ultimately, this elongation reaction sequence repeats through 7 cycles to form one molecule of (16C) palmitate, as malonyl-CoA (the carbon donor) adds 2 carbons to the growing chain per cycle. During the third reaction of fatty acid synthesis, acetyl-ACP and malonyl-ACP undergo a condensation reaction catalyzed by the enzyme β-ketoacyl-ACP synthase (also known as acyl-malonyl-ACP condensing enzyme), which produces the four-carbon acetoacetyl-ACP molecule and one molecule of CO2. Notably, the reaction of two-carbon acetyl-ACP with three-carbon malonyl-ACP is more favorable than that of two, two-carbon acetyl-ACP molecules reacting together. The fourth step of fatty acid elongation is the reduction of acetoacyl-ACP to β-hydroxyacyl-ACP, in a reaction catalyzed by 3-ketoacyl-ACP reductase.
=== Protein divergence === C3orf52 is evolving more quickly than other common proteins including cytochrome c and fibrinogen alpha chain. This would suggest some sort of selective pressure on the protein driving its rapid evolution.
Human chorionic gonadotropin (hCG) is a hormone for the maternal recognition of pregnancy produced by trophoblast cells that are surrounding a growing embryo (syncytiotrophoblast initially), which eventually forms the placenta after implantation. The presence of hCG is detected in some pregnancy tests (HCG pregnancy strip tests). Some cancerous tumors produce this hormone; therefore, elevated levels measured when the patient is not pregnant may lead to a diagnosis of cancer and, if high enough, of paraneoplastic syndromes. It is unknown however whether this production is a contributing cause or an effect of carcinogenesis. The pituitary analogue of hCG, luteinizing hormone (LH), is produced in the pituitary gland of males and females of all ages. Beta-hCG is initially secreted by the syncytiotrophoblast.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.